Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,179,168
  • Shares Outstanding, K 52,712
  • Annual Sales, $ 55,510 K
  • Annual Income, $ -346,400 K
  • 36-Month Beta 1.74
  • Price/Sales 15.03
  • Price/Cash Flow N/A
  • Price/Book 5.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.74
  • Number of Estimates 5
  • High Estimate -1.57
  • Low Estimate -1.84
  • Prior Year -1.27
  • Growth Rate Est. (year over year) -37.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.55 +45.02%
on 12/24/18
25.38 -5.44%
on 01/10/19
+5.12 (+27.12%)
since 12/18/18
3-Month
11.50 +108.70%
on 10/31/18
30.90 -22.33%
on 10/19/18
-5.96 (-19.89%)
since 10/18/18
52-Week
11.50 +108.70%
on 10/31/18
65.97 -63.62%
on 01/23/18
-31.87 (-57.04%)
since 01/18/18

Most Recent Stories

More News
Immunomedics Gets CRL From FDA for Breast Cancer Candidate

Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.

AZN : 36.55 (+0.72%)
CLVS : 24.00 (+7.29%)
RHHBY : 32.6100 (+0.59%)
IMMU : 13.31 (-26.42%)
CLVS March 15th Options Begin Trading

Investors in Clovis Oncology Inc saw new options become available today, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLVS options chain...

CLVS : 24.00 (+7.29%)
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

CLVS : 24.00 (+7.29%)
Clovis Oncology has the Best Relative Performance in the Biotechnology Industry (CLVS , CHRS , EPZM , CYTK , EXEL )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CHRS : 11.72 (+5.49%)
CLVS : 24.00 (+7.29%)
EPZM : 9.56 (unch)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Blueprint Medici (BPMC , NVTA , CLVS , EXAS , ARRY )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

NVTA : 14.94 (+4.33%)
CLVS : 24.00 (+7.29%)
BPMC : 70.02 (+4.13%)
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018

--Q4/FY2018 Operating Results planned for February 26, 2019

CLVS : 24.00 (+7.29%)
Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 37th Annual J.P. Morgan Healthcare Conference...

JPM : 104.59 (+1.62%)
CLVS : 24.00 (+7.29%)
Immunomedics Enters Into Supply Deal for Breast Cancer Drug

Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.

AZN : 36.55 (+0.72%)
CLVS : 24.00 (+7.29%)
IMMU : 13.31 (-26.42%)
BMY : 50.12 (+1.05%)
AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting

AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.

AZN : 36.55 (+0.72%)
MRK : 75.87 (+0.36%)
CLVS : 24.00 (+7.29%)
TSRO : 74.96 (+0.03%)
Clovis Oncology Up 19.4% Since SmarTrend Uptrend Call (CLVS)

SmarTrend identified an Uptrend for Clovis Oncology (NASDAQ:CLVS) on November 20th, 2018 at $16.84. In approximately 3 weeks, Clovis Oncology has returned 19.42% as of today's recent price of $20.11.

CLVS : 24.00 (+7.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators mostly agree with the trend.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 25.71
1st Resistance Point 24.85
Last Price 24.00
1st Support Level 22.40
2nd Support Level 20.81

See More

52-Week High 65.97
Fibonacci 61.8% 45.16
Fibonacci 50% 38.74
Fibonacci 38.2% 32.31
Last Price 24.00
52-Week Low 11.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar